Artiva Biotherapeutics (ARTV) Profit After Tax (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Profit After Tax for 4 consecutive years, with -$23.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 16.38% year-over-year to -$23.6 million; the TTM figure through Mar 2026 stood at -$87.0 million (down 20.46% YoY), while the FY2025 annual figure was -$83.6 million, down 27.08% from the prior year.
• Profit After Tax retreated to -$23.6 million in Q1 2026 per ARTV's latest filing, from -$20.5 million in the prior quarter.
• Across five years, Profit After Tax topped out at $11.4 million in Q3 2023 and bottomed at -$23.6 million in Q1 2026.
• Historically, Profit After Tax has averaged -$15.4 million across 4 years, with a median of -$17.7 million in 2024.
• Annual changes were most pronounced in 2024 — Profit After Tax sank 252.95% — and 2026, when it slipped 16.38%.
• Artiva Biotherapeutics' Profit After Tax stood at -$12.3 million in 2023, then sank by 34.99% to -$16.6 million in 2024, then declined by 24.02% to -$20.5 million in 2025, then declined by 15.08% to -$23.6 million in 2026.
• Business Quant data shows ARTV's Profit After Tax at -$23.6 million in Q1 2026, -$20.5 million in Q4 2025, and -$21.5 million in Q3 2025.